Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Trends that Matter for Medicare Coverage

Posted by Matt Breese on May 4, 2016

Find me on:

The following infographics highlight how Medicare health plans cover treatments in trending therapeutic areas. Typically, Medicare Part D formularies implement more restrictive reimbursement controls, as compared to commercial formularies.

Immunology: This category includes treatments indicated for rheumatoid arthritis, Crohn's, psoriatic arthritis and psoriasis. For Medicare Part D formularies, these treatments are not covered for 52% of payer-controlled lives, with another 42% restricted by PA or step therapy policies. Click on the image to view more.

reality-check-immunology-v1.png

Cystic Fibrosis: An analysis of payer pharmacy benefit coverage for Medicare Part D plan sponsors shows that formularies do not cover CF treatments for around one-quarter of lives, with an additional one-half of lives restricted by a PA or step therapy. Click on the image to view more.

cystic-fibrosis-reality-check.png

 

Multiple Sclerosis: A review of payer-controlled pharmacy benefit coverage for MS treatments shows that over 9 in 10 lives are either restricted by utilization management policies or not covered entirely. Click on the image to view more.

reality-check-ms-march2.png

Narcotic Pain: For narcotic pain treatments, 9% of payer-controlled Medicare Part D lives are restricted by PA or step therapies and around 80% of these formularies do not cover the average branded narcotic pain treatment. Click on the image to view more.

reality-check-pain-narcotic.png

Subscribe to the MMIT blog for more managed care and market access trends, with perspectives from payers and providers.

Subscribe for Weekly Trends that Matter

Topics: Specialty, Industry Trends, Payer